The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Research Report: Human ENDOU (Placental Protein 11; UniProt P21128) — Functional Annotation

1) Target identity verification (critical disambiguation)

The gene symbol ENDOU in Homo sapiens encodes placental protein 11 (PP11), a member of the eukaryotic EndoU-family endoribonucleases. The key primary biochemical study explicitly analyzes human PP11/ENDOU (UniProt P21128) and establishes its enzymatic identity, distinguishing it from the viral nidoviral EndoU (coronavirus nsp15) that is often discussed in parallel due to homology. Throughout this report, mechanistic claims are supported only when the cited source explicitly addresses human ENDOU/PP11 rather than viral EndoU. (laneve2008thetumormarker pages 1-2, laneve2008thetumormarker pages 2-3)

2) Key concepts and definitions (current understanding)

2.1 What ENDOU is

Human ENDOU/PP11 is an uridylate-specific endoribonuclease (an RNase) that binds and cleaves RNA internally (endoribonucleolysis), rather than a protease. This corrected earlier annotations that had labeled PP11 as a serine protease; biochemical testing on recombinant protein found no detectable protease activity, supporting reclassification as an RNase. (laneve2008thetumormarker pages 1-2, laneve2008thetumormarker pages 7-8, laneve2008thetumormarker pages 3-5)

2.2 Reaction chemistry and products

Laneve et al. (2008, Journal of Biological Chemistry, Dec 2008) demonstrated that recombinant human ENDOU cleaves single-stranded RNA to generate products bearing 2′,3′-cyclic phosphate termini—an important mechanistic signature shared with related EndoU-family RNases. (laneve2008thetumormarker pages 1-2, laneve2008thetumormarker pages 2-3, laneve2008thetumormarker pages 6-7)

2.3 Substrate specificity and cofactors

Biochemical assays showed ENDOU is uridylate-directed (cleaves at/near uridylate residues) and is Mn²⁺-dependent under the tested in vitro conditions. In that study, activity was evaluated using defined oligoribonucleotide substrates and reaction buffers that included MnCl₂; cleavage preferences were reported around dinucleotide contexts including GU, UA, AU, CU, UU, and UC (interpretable as sequence-context preferences flanking uridylates). (laneve2008thetumormarker pages 1-2, laneve2008thetumormarker pages 6-7, laneve2008thetumormarker pages 7-8)

More recent mechanistic work (outside the requested 2023–2024 window but directly informative) supports that eukaryotic EndoU enzymes can be divalent metal–regulated, with human EndoU exhibiting calcium-dependent activation through an allosteric mechanism involving its N-terminal extension and catalytic core. (Malard et al., Nature Communications, Apr 2025; https://doi.org/10.1038/s41467-025-58462-6) (malard2025molecularbasisfor pages 1-2)

2.4 Catalytic residues and structural features

Laneve et al. combined homology modeling (using Xenopus XendoU as a template; PDB 2c1w) with site-directed mutagenesis and identified residues required for cleavage activity: E243, H244, E249, H259, and K302 (human numbering as reported). Mutants substantially lost processing activity while retaining RNA-binding in mobility-shift assays, supporting these residues as part of the functional catalytic apparatus. The authors also highlighted a flexible loop/flap (Gly248–Asn260) in the predicted RNA-binding region as a candidate determinant of binding and specificity. (Laneve et al., JBC, Dec 2008; https://doi.org/10.1074/jbc.m805759200) (laneve2008thetumormarker pages 2-3, laneve2008thetumormarker pages 6-7, laneve2008thetumormarker pages 7-8, laneve2008thetumormarker pages 3-5)

3) Cellular localization, processing, and expression contexts

3.1 Placental expression and cell-type localization

ENDOU/PP11 was initially isolated as a placenta-derived glycoprotein and is described as highly expressed in the syncytiotrophoblast. Prior localization work cited by Laneve et al. reported PP11 to be exclusively localized in the cytoplasm of syncytiotrophoblast. (laneve2008thetumormarker pages 1-2, laneve2008thetumormarker pages 2-3)

3.2 Precursor vs mature forms (processing)

When PP11 cDNA was expressed in E. coli, two forms were reported: a ~45 kDa precursor and a ~42 kDa mature protein. Laneve et al. purified and studied a recombinant His-tagged form corresponding to the mature protein in enzymatic assays. (laneve2008thetumormarker pages 1-2, laneve2008thetumormarker pages 2-3)

3.3 Placental pathology: preeclampsia/fetal growth restriction

Proteomics on isolated placental cytotrophoblasts found ENDOU to be upregulated in placentas complicated by preeclampsia with fetal growth restriction (PE-FGR) relative to controls, suggesting ENDOU expression changes may be a feature of placental hypoplasia/pathophysiology (study design: LC–MS/MS differential proteomics). (Nomoto et al., J Clin Biochem Nutr, Jul 2021; https://doi.org/10.3164/jcbn.21-37) (nomoto2021upregulationofendou pages 4-5, nomoto2021upregulationofendou pages 6-6)

4) Biological roles and pathway-level interpretation

4.1 Proposed physiological role: RNA metabolism and possibly host defense

Given its cytoplasmic localization in syncytiotrophoblast and biochemical RNase activity, Laneve et al. proposed that PP11 could contribute to placental physiology via RNA recognition and degradation, including a hypothesis that RNA binding/cleavage might help recognize viral RNAs or mRNAs (a proposed role rather than a direct demonstration of endogenous substrates). (laneve2008thetumormarker pages 8-8)

4.2 Emerging role: post-transcriptional regulation linked to lipid homeostasis (2023)

A major recent development is a 2023 Nature Communications study in Drosophila identifying an EndoU-family RNase (Arlr) as a regulator of lipid droplet homeostasis during aging. Importantly for human ENDOU annotation, the study reports that transgenic full-length human ENDOU expressed in fly fat body rescued arlr mutant phenotypes (lipid droplet size and total triacylglycerol levels) and reduced mRNA levels of candidate lipolysis genes in that mutant background, supporting conserved EndoU-family functionality in mRNA-level regulation relevant to lipid metabolism. This provides experimental evidence for a conserved capacity of human ENDOU to functionally substitute for an EndoU-family RNase in vivo (cross-species rescue), though it does not identify native human ENDOU targets in human tissues. (Sun et al., Nature Communications, Oct 2023; https://doi.org/10.1038/s41467-023-42042-7) (sun2023theendoribonucleasearlr pages 6-7, sun2023theendoribonucleasearlr pages 1-2)

4.3 Evolutionary context (expert synthesis from comparative genomics)

An evolutionary analysis supports that EndoU-family RNases are part of an ancient RNase lineage with an evolutionary connection to RNase A-like folds, reinforcing that ENDOU is best interpreted as a conserved RNase domain protein rather than a placenta-specific oddity. (Mushegian et al., RNA, Apr 2020; https://doi.org/10.1261/rna.074385.119) (OpenTargets Search: -ENDOU)

5) Current applications and real-world implementations

5.1 ENDOU as a tumor marker / cancer biomarker (reported statistics)

Laneve et al. summarize prior tumor-marker reports for PP11/ENDOU and provide explicit detection frequencies:
- 66.7% of analyzed mucinous cystadenocarcinomas
- 57.1% of analyzed serous cystadenocarcinomas
- 47% of breast cancers
- 38% of testicular and gastric cancers
with absence in normal ovaries (as reported in the cited tumor-marker context). These values reflect historical tumor-marker literature summarized in the 2008 biochemical reclassification paper. (Laneve et al., J Biol Chem, Dec 2008; https://doi.org/10.1074/jbc.m805759200) (laneve2008thetumormarker pages 1-2)

Two later oncology studies (bioinformatics + experimental validation) extend biomarker applications:
- In head and neck squamous cell carcinoma (HNSCC), ENDOU was identified as an independent survival marker candidate; ENDOU overexpression reduced proliferation and migration in cell lines in that study’s model system. (Xu et al., Frontiers in Oncology, Feb 2021; https://doi.org/10.3389/fonc.2020.522332) (OpenTargets Search: -ENDOU)
- In cervical squamous cell carcinoma, a transcriptomic meta-analysis selected ENDOU as a candidate diagnostic biomarker and immunohistochemistry reported ~1% positivity in tumors vs ~40% positivity in non-tumor tissues (in the cohort examined), consistent with reduced expression in tumor. (Bašić et al., Oncology Letters, Oct 2021; https://doi.org/10.3892/ol.2021.13101) (OpenTargets Search: -ENDOU)

5.2 Pregnancy medicine: placental proteomics signal

ENDOU’s upregulation in PE-FGR cytotrophoblasts suggests potential use as a placental pathology biomarker or mechanistic clue for disease, though causality and clinical utility require validation in larger cohorts. (Nomoto et al., Jul 2021; https://doi.org/10.3164/jcbn.21-37) (nomoto2021upregulationofendou pages 4-5, nomoto2021upregulationofendou pages 6-6)

6) Recent developments (prioritizing 2023–2024) and limitations

6.1 2023: conserved in vivo function in lipid regulation

The strongest 2023 primary evidence retrieved here is the cross-species functional study showing human ENDOU can rescue an EndoU-family lipid phenotype in vivo in flies, supporting a broader physiological scope for ENDOU-like RNases beyond placenta/tumor-marker contexts. (Sun et al., Oct 2023; https://doi.org/10.1038/s41467-023-42042-7) (sun2023theendoribonucleasearlr pages 6-7, sun2023theendoribonucleasearlr pages 1-2)

6.2 2024: limited direct ENDOU-specific primary evidence retrieved in this run

A targeted 2023–2024 literature search retrieved few directly relevant full-text ENDOU mechanistic studies for humans; therefore, 2024 ENDOU-specific advances (e.g., new human interactomes, endogenous RNA targetomes, new structures, or clinical validations) could not be comprehensively summarized from the currently retrieved corpus. This report therefore emphasizes validated mechanistic foundations (2008) plus the most relevant recent functional work available (2023). (laneve2008thetumormarker pages 1-2, sun2023theendoribonucleasearlr pages 1-2)

7) Expert opinion and integrative analysis (evidence-based)

1. Primary functional annotation: The most defensible primary function of human ENDOU is as a Mn²⁺-dependent uridylate-directed endoribonuclease producing 2′,3′-cyclic phosphate ends. This is supported by direct biochemical assays and product characterization. (laneve2008thetumormarker pages 1-2, laneve2008thetumormarker pages 6-7)
2. Mechanistic architecture: Mutagenesis indicates a catalytic constellation including E243/H244/E249/H259/K302 and structural modeling indicates an RNA-binding region with a flexible flap/loop, consistent with an RNase that may have regulated substrate docking and sequence context effects. (laneve2008thetumormarker pages 6-7, laneve2008thetumormarker pages 7-8)
3. Physiological context: Strong placental expression and cytoplasmic localization in syncytiotrophoblast support a plausible role in cytoplasmic RNA metabolism in trophoblast biology; tumor re-expression suggests that ENDOU expression may mark or contribute to invasive/differentiation states, but the directionality remains context-specific across cancer types. (laneve2008thetumormarker pages 1-2, laneve2008thetumormarker pages 7-8)
4. Broader biological scope (2023): Cross-species rescue of lipid phenotypes argues that ENDOU-family RNases may participate in mRNA-level regulation in metabolic homeostasis, motivating targeted studies in human metabolic tissues. (sun2023theendoribonucleasearlr pages 6-7)

8) Disease association resources (database evidence)

Open Targets lists disease associations for ENDOU with low-to-moderate scores across several conditions (e.g., cardiovascular disease, age-related macular degeneration, kidney disease, basal cell carcinoma, retinitis pigmentosa), but the evidence entries retrieved here did not include linked PubMed/PMC identifiers; therefore these should be treated as hypothesis-generating rather than definitive without underlying study inspection. (OpenTargets Search: -ENDOU)

Summary table of key evidence

Table: This table compiles the most relevant evidence for human ENDOU/PP11 across foundational biochemistry, placental pathology, cancer biomarker studies, evolutionary inference, and recent cross-species functional work. It emphasizes experimentally supported claims and separates mechanistic human ENDOU findings from broader EndoU-family context.

References (URLs and publication dates)

• Laneve P. et al. The tumor marker human placental protein 11 is an endoribonuclease. Journal of Biological Chemistry. Dec 2008. https://doi.org/10.1074/jbc.m805759200 (laneve2008thetumormarker pages 1-2)
• Nomoto M. et al. Upregulation of ENDOU in cytotrophoblasts from placenta complicated with preeclampsia and fetal growth restriction. J Clin Biochem Nutr. Jul 2021. https://doi.org/10.3164/jcbn.21-37 (nomoto2021upregulationofendou pages 4-5)
• Sun X. et al. The endoribonuclease Arlr is required to maintain lipid homeostasis by downregulating lipolytic genes during aging. Nature Communications. Oct 2023. https://doi.org/10.1038/s41467-023-42042-7 (sun2023theendoribonucleasearlr pages 1-2)
• Mushegian A. et al. An ancient evolutionary connection between Ribonuclease A and EndoU families. RNA. Apr 2020. https://doi.org/10.1261/rna.074385.119 (OpenTargets Search: -ENDOU)
• Malard F. et al. Molecular basis for the calcium-dependent activation of the ribonuclease EndoU. Nature Communications. Apr 2025. https://doi.org/10.1038/s41467-025-58462-6 (mechanistic; outside 2023–2024) (malard2025molecularbasisfor pages 1-2)
• Xu C. et al. Integrated Analysis Reveals ENDOU as a Biomarker in Head and Neck Squamous Cell Carcinoma Progression. Frontiers in Oncology. Feb 2021. https://doi.org/10.3389/fonc.2020.522332 (OpenTargets Search: -ENDOU)
• Bašić V. et al. Integrative meta-analysis of gene expression profiles identifies FEN1 and ENDOU as potential diagnostic biomarkers for cervical squamous cell carcinoma. Oncology Letters. Oct 2021. https://doi.org/10.3892/ol.2021.13101 (OpenTargets Search: -ENDOU)

References

1. (laneve2008thetumormarker pages 1-2): Pietro Laneve, Ubaldo Gioia, Rino Ragno, Fabio Altieri, Carmen Di Franco, Tiziana Santini, Massimo Arceci, Irene Bozzoni, and Elisa Caffarelli. The tumor marker human placental protein 11 is an endoribonuclease*. Journal of Biological Chemistry, 283:34712-34719, Dec 2008. URL: https://doi.org/10.1074/jbc.m805759200, doi:10.1074/jbc.m805759200. This article has 65 citations and is from a domain leading peer-reviewed journal.

2. (laneve2008thetumormarker pages 2-3): Pietro Laneve, Ubaldo Gioia, Rino Ragno, Fabio Altieri, Carmen Di Franco, Tiziana Santini, Massimo Arceci, Irene Bozzoni, and Elisa Caffarelli. The tumor marker human placental protein 11 is an endoribonuclease*. Journal of Biological Chemistry, 283:34712-34719, Dec 2008. URL: https://doi.org/10.1074/jbc.m805759200, doi:10.1074/jbc.m805759200. This article has 65 citations and is from a domain leading peer-reviewed journal.

3. (laneve2008thetumormarker pages 7-8): Pietro Laneve, Ubaldo Gioia, Rino Ragno, Fabio Altieri, Carmen Di Franco, Tiziana Santini, Massimo Arceci, Irene Bozzoni, and Elisa Caffarelli. The tumor marker human placental protein 11 is an endoribonuclease*. Journal of Biological Chemistry, 283:34712-34719, Dec 2008. URL: https://doi.org/10.1074/jbc.m805759200, doi:10.1074/jbc.m805759200. This article has 65 citations and is from a domain leading peer-reviewed journal.

4. (laneve2008thetumormarker pages 3-5): Pietro Laneve, Ubaldo Gioia, Rino Ragno, Fabio Altieri, Carmen Di Franco, Tiziana Santini, Massimo Arceci, Irene Bozzoni, and Elisa Caffarelli. The tumor marker human placental protein 11 is an endoribonuclease*. Journal of Biological Chemistry, 283:34712-34719, Dec 2008. URL: https://doi.org/10.1074/jbc.m805759200, doi:10.1074/jbc.m805759200. This article has 65 citations and is from a domain leading peer-reviewed journal.

5. (laneve2008thetumormarker pages 6-7): Pietro Laneve, Ubaldo Gioia, Rino Ragno, Fabio Altieri, Carmen Di Franco, Tiziana Santini, Massimo Arceci, Irene Bozzoni, and Elisa Caffarelli. The tumor marker human placental protein 11 is an endoribonuclease*. Journal of Biological Chemistry, 283:34712-34719, Dec 2008. URL: https://doi.org/10.1074/jbc.m805759200, doi:10.1074/jbc.m805759200. This article has 65 citations and is from a domain leading peer-reviewed journal.

6. (malard2025molecularbasisfor pages 1-2): Florian Malard, Kristen Dias, Margaux Baudy, Stéphane Thore, Brune Vialet, Philippe Barthélémy, Sébastien Fribourg, Fedor Karginov, and Sebastien Campagne. Molecular basis for the calcium-dependent activation of the ribonuclease endou. Nature Communications, Apr 2025. URL: https://doi.org/10.1038/s41467-025-58462-6, doi:10.1038/s41467-025-58462-6. This article has 7 citations and is from a highest quality peer-reviewed journal.

7. (nomoto2021upregulationofendou pages 4-5): Masataka Nomoto, Tomomi Kotani, Rika Miki, Takafumi Ushida, Kenji Imai, Yukako Iitani, Sho Tano, Jingwen Wang, Yoshinori Moriyama, Tomoko Kobayashi, Nobuko Mimura, Takayuki Iriyama, Fumitaka Kikkawa, and Hiroaki Kajiyama. Upregulation of endou in cytotrophoblasts from placenta complicated with preeclampsia and fetal growth restriction. Journal of Clinical Biochemistry and Nutrition, 69:280-285, Jul 2021. URL: https://doi.org/10.3164/jcbn.21-37, doi:10.3164/jcbn.21-37. This article has 0 citations and is from a peer-reviewed journal.

8. (nomoto2021upregulationofendou pages 6-6): Masataka Nomoto, Tomomi Kotani, Rika Miki, Takafumi Ushida, Kenji Imai, Yukako Iitani, Sho Tano, Jingwen Wang, Yoshinori Moriyama, Tomoko Kobayashi, Nobuko Mimura, Takayuki Iriyama, Fumitaka Kikkawa, and Hiroaki Kajiyama. Upregulation of endou in cytotrophoblasts from placenta complicated with preeclampsia and fetal growth restriction. Journal of Clinical Biochemistry and Nutrition, 69:280-285, Jul 2021. URL: https://doi.org/10.3164/jcbn.21-37, doi:10.3164/jcbn.21-37. This article has 0 citations and is from a peer-reviewed journal.

9. (laneve2008thetumormarker pages 8-8): Pietro Laneve, Ubaldo Gioia, Rino Ragno, Fabio Altieri, Carmen Di Franco, Tiziana Santini, Massimo Arceci, Irene Bozzoni, and Elisa Caffarelli. The tumor marker human placental protein 11 is an endoribonuclease*. Journal of Biological Chemistry, 283:34712-34719, Dec 2008. URL: https://doi.org/10.1074/jbc.m805759200, doi:10.1074/jbc.m805759200. This article has 65 citations and is from a domain leading peer-reviewed journal.

10. (sun2023theendoribonucleasearlr pages 6-7): Xiaowei Sun, Jie Shen, Norbert Perrimon, Xue Kong, and Dan Wang. The endoribonuclease arlr is required to maintain lipid homeostasis by downregulating lipolytic genes during aging. Nature Communications, Oct 2023. URL: https://doi.org/10.1038/s41467-023-42042-7, doi:10.1038/s41467-023-42042-7. This article has 13 citations and is from a highest quality peer-reviewed journal.

11. (sun2023theendoribonucleasearlr pages 1-2): Xiaowei Sun, Jie Shen, Norbert Perrimon, Xue Kong, and Dan Wang. The endoribonuclease arlr is required to maintain lipid homeostasis by downregulating lipolytic genes during aging. Nature Communications, Oct 2023. URL: https://doi.org/10.1038/s41467-023-42042-7, doi:10.1038/s41467-023-42042-7. This article has 13 citations and is from a highest quality peer-reviewed journal.

12. (OpenTargets Search: -ENDOU): Open Targets Query (-ENDOU, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

Artifacts

• Edison artifact artifact-00

Citations

1. malard2025molecularbasisfor pages 1-2
2. laneve2008thetumormarker pages 8-8
3. laneve2008thetumormarker pages 1-2
4. sun2023theendoribonucleasearlr pages 6-7
5. nomoto2021upregulationofendou pages 4-5
6. sun2023theendoribonucleasearlr pages 1-2
7. laneve2008thetumormarker pages 2-3
8. laneve2008thetumormarker pages 7-8
9. laneve2008thetumormarker pages 3-5
10. laneve2008thetumormarker pages 6-7
11. nomoto2021upregulationofendou pages 6-6
12. https://doi.org/10.1038/s41467-025-58462-6
13. https://doi.org/10.1074/jbc.m805759200
14. https://doi.org/10.3164/jcbn.21-37
15. https://doi.org/10.1038/s41467-023-42042-7
16. https://doi.org/10.1261/rna.074385.119
17. https://doi.org/10.3389/fonc.2020.522332
18. https://doi.org/10.3892/ol.2021.13101
19. https://doi.org/10.1074/jbc.m805759200,
20. https://doi.org/10.1038/s41467-025-58462-6,
21. https://doi.org/10.3164/jcbn.21-37,
22. https://doi.org/10.1038/s41467-023-42042-7,

Human ENDOU (Uridylate-Specific Endoribonuclease) – Functional Annotation

Identification and Key Characteristics

Human ENDOU is an endoribonuclease (RNA-cleaving enzyme) with specificity for uridine-rich RNA sequences (pmc.ncbi.nlm.nih.gov). It was originally identified in the placenta and named placental protein 11 (PP11) due to its high abundance in placental tissue (pmc.ncbi.nlm.nih.gov). Early cloning studies (c. 1990) mischaracterized this gene product as a putative serine protease (designated PRSS26) and tumor marker (www.ncbi.nlm.nih.gov), because its sequence contains motifs that resembled protease domains. However, subsequent biochemical research demonstrated that PP11 is in fact an endonuclease: it cleaves single-stranded RNA molecules, preferentially cutting at sites 5′ to uridylate (uridine) residues (pmc.ncbi.nlm.nih.gov). This uridylate-specific activity earned it the name endonuclease, poly(U)-specific. ENDOU is conserved across diverse eukaryotes – from plants and insects to mammals – defining a distinct EndoU family with no homology to other RNase families (pmc.ncbi.nlm.nih.gov). Notably, its amino-acid sequence and fold are distinct from the well-known RNase A family, although there is evidence of a distant evolutionary link between EndoU and RNase A enzymes (pmc.ncbi.nlm.nih.gov).

Structural Features and Enzymatic Mechanism

The ENDOU protein is synthesized as a precursor ~410 amino acids in length and contains an N-terminal signal peptide followed by two Somatomedin B-like (SMB) domains rich in disulfide bonds (pmc.ncbi.nlm.nih.gov). These SMB domains are small protein modules also found in vitronectin and other secreted proteins, and their presence in ENDOU suggests a secretory or ER-associated localization (pmc.ncbi.nlm.nih.gov). The C-terminal portion of ENDOU comprises the catalytic EndoU domain (sometimes called the XendoU domain, by homology to the Xenopus enzyme) which harbors the active site. Structural and mutational analyses indicate that ENDOU’s active site employs a His-His-Lys catalytic triad, analogous to that of RNase A (pmc.ncbi.nlm.nih.gov). In other words, two histidine residues and one lysine act as general acid/base catalysts to cleave RNA phosphodiester bonds. This mechanism enables ENDOU to cut RNA endonucleolytically, likely yielding a 2′,3′-cyclic phosphate and 5′-hydroxyl at the cleavage site (as is typical for RNase A-like enzymes). Consistent with this catalytic mechanism, the crystal structure of a related XendoU enzyme revealed an RNase A-like active site configuration (pmc.ncbi.nlm.nih.gov). Human ENDOU’s enzymatic activity requires divalent metal ions, a unique feature distinguishing eukaryotic EndoU family members (pmc.ncbi.nlm.nih.gov). Biochemical assays have shown that purified human or Xenopus EndoU is largely inactive on RNA unless millimolar concentrations of Ca²⁺ (or Mn²⁺) are present (pmc.ncbi.nlm.nih.gov). Recent high-resolution studies have illuminated the basis for this calcium dependence: in 2024, Malard et al. solved the crystal structure of human ENDOU bound to Ca²⁺ and showed that calcium binding triggers an allosteric conformational change that activates the enzyme (pmc.ncbi.nlm.nih.gov). The Ca²⁺ ion binds at a site remote from the catalytic triad, bridging parts of the N-terminal extension and the core; this interaction induces structural rearrangements that align the catalytic residues properly for RNA cleavage (pmc.ncbi.nlm.nih.gov). Thus, calcium acts as a molecular switch for ENDOU, ensuring the RNase is active only under specific cellular conditions. This calcium-driven “on/off” regulation is a distinctive evolutionary adaptation of eukaryotic EndoU nucleases (pmc.ncbi.nlm.nih.gov), in contrast to bacterial or viral homologs that are constitutively active.

Expression and Localization

ENDOU is not a ubiquitously expressed housekeeping gene; rather, its expression is restricted to select cell types and tissues. As mentioned, it is highly expressed in the placenta (explaining its discovery in that tissue) (pmc.ncbi.nlm.nih.gov). Transcriptomic data indicate ENDOU is also expressed in certain adult tissues – for example, relatively high mRNA levels are observed in esophageal epithelium and skin (www.ncbi.nlm.nih.gov) – though most other tissues show low baseline expression. In the immune system, ENDOU expression is cell-type specific: analysis of mouse data from the Immunological Genome Project found EndoU transcripts are strongly upregulated in developing thymocytes (T cells) and in subsets of B cells (pmc.ncbi.nlm.nih.gov). Indeed, ENDOU appears to be induced during specific differentiation or stress conditions (see below).

At the subcellular level, ENDOU is a secretory pathway protein by virtue of its signal peptide and disulfide-bonded domains. After translation, the protein enters the endoplasmic reticulum (ER) lumen and is glycosylated (human ENDOU has predicted N-glycosylation sites, as is common for secreted glycoproteins ). Some ENDOU molecules are ultimately secreted from the cell, and interestingly, studies suggest secreted EndoU enzymes can even be taken up by neighboring cells (pmc.ncbi.nlm.nih.gov). Other family members may remain in the ER or Golgi compartments, functioning within the cell’s endomembrane system (pmc.ncbi.nlm.nih.gov). In Xenopus laevis eggs, for example, EndoU (XendoU) localizes to the ER, where it plays a role in ER network formation (pmc.ncbi.nlm.nih.gov). The human ENDOU protein likely follows a similar paradigm: it is synthesized into the ER lumen and may function there or in the extracellular space. Its two SMB domains could facilitate interactions with extracellular matrix or cell-surface components, although the exact binding partners are not well characterized. It is important to note that alternative splicing of the ENDOU gene yields multiple isoforms (at least three) (www.ncbi.nlm.nih.gov), which might have differing N-termini. It has been speculated that some isoforms could lack the signal peptide and remain intracellular, but the predominant isoform (isoform 1) is a secreted glycoprotein de facto. Experimental evidence in human cells (and analogously in frog oocytes) supports the idea that ENDOU can act within the secretory compartment – for instance, by degrading RNA locally in the ER lumen to influence organelle morphology (pmc.ncbi.nlm.nih.gov).

Biological Functions and Pathways

RNA Processing and Turnover: ENDOU’s canonical function is as an endoribonuclease that cleaves single-stranded RNAs, especially at U-rich sites. This activity links ENDOU to several RNA-processing events. In the original model organism study, Xenopus EndoU was found to process intronic snoRNA precursors – it cleaved pre-rRNA intron sequences to release small nucleolar RNAs (snoRNAs) (pmc.ncbi.nlm.nih.gov), thereby aiding snoRNP maturation. This suggests a role in ribonucleoprotein (RNP) particle remodeling or removal, by cutting out specific RNA fragments. Consistent with that, human ENDOU has been proposed to help eliminate certain RNA fragments or RNP complexes in cells (pmc.ncbi.nlm.nih.gov). Its preference for poly(U) regions may target it to transcripts or non-coding RNAs that are U-rich, possibly including regulatory RNAs or repetitive transcripts. ENDOU does not appear to indiscriminately degrade all RNAs, but rather acts on specific substrates – as evidenced by recent findings on mRNA targets (see below).

Endoplasmic Reticulum Dynamics: A striking function for ENDOU was uncovered in Xenopus egg extracts, where XendoU activity was required for normal ER network formation (pmc.ncbi.nlm.nih.gov). The mechanism, as described by Schwarz and Blower (2014), is that XendoU’s calcium-activated RNase activity locally degrades RNA tethered to the ER, which helps remodel the ER’s structure (pmc.ncbi.nlm.nih.gov). In the absence of EndoU, excess RNA on the ER may lead to overly stable ribosome–translocon interactions or RNP aggregates that hinder the web-like ER network from extending properly (pmc.ncbi.nlm.nih.gov). The calcium dependence of ENDOU is particularly relevant here, since calcium levels fluctuate in the ER; ENDOU might become active during calcium signaling events to transiently cleave RNAs and facilitate dynamic changes in the ER architecture. While this has been demonstrated in Xenopus, human ENDOU likely performs an analogous role in cells that require large-scale ER remodeling (e.g. during B cell plasma cell differentiation or in oocyte maturation), although direct evidence in human cells is still emerging. A related concept is that ENDOU might help dispose of mislocalized RNAs in the secretory pathway, protecting the cell from potential RNA:protein aggregation stress in the ER lumen (pmc.ncbi.nlm.nih.gov).

Regulation of mRNA Translation in Stress: One of the most intriguing discoveries about ENDOU’s function came from a 2021 study on the cellular stress response. This work showed that ENDOU can selectively promote translation of specific mRNAs by cleaving inhibitory RNA elements. In particular, CHOP mRNA, which encodes a pro-apoptotic transcription factor activated during ER stress, contains an upstream open reading frame (uORF) that normally suppresses its translation. Researchers found that human ENDOU (and its zebrafish ortholog Endouc) binds to the CHOP mRNA 5′ leader and cleaves within the uORF element, thereby relieving the translational block (pubmed.ncbi.nlm.nih.gov). ENDOU cuts the CHOP uORF at a specific site (between a G and a U nucleotide in the uORF sequence), generating a truncated mRNA segment (pubmed.ncbi.nlm.nih.gov). This cleavage allows ribosomes to bypass the uORF and re-initiate at the main coding sequence, markedly increasing CHOP protein synthesis (pubmed.ncbi.nlm.nih.gov). Notably, ENDOU’s effect was sufficient to induce CHOP translation even in the absence of other stress signals (pubmed.ncbi.nlm.nih.gov). Under actual stress conditions (such as the unfolded protein response, which phosphorylates eIF2α), ENDOU and the integrated stress signaling act synergistically – maximal CHOP expression required both ENDOU and eIF2α phosphorylation (pubmed.ncbi.nlm.nih.gov). The proposed model is that ENDOU-mediated cleavage of the CHOP mRNA is a regulatory switch: it converts the mRNA into a form that can be translated via an internal ribosome entry site (IRES) in the truncated transcript (pubmed.ncbi.nlm.nih.gov). This allows rapid production of CHOP protein, which drives stress-induced apoptosis. In summary, ENDOU serves as a translational control factor under stress, fine-tuning the expression of stress-response genes by targeted RNA cleavage. This specific example with CHOP suggests ENDOU might have other mRNA targets with uORFs or structured 5′ UTRs, through which it can modulate protein synthesis in response to cellular signals.

Immune Cell Apoptosis and Self-Tolerance: Another major function of ENDOU is in the immune system, particularly in regulating B cell activation-induced cell death (AICD). AICD is a mechanism that eliminates self-reactive or over-activated B cells to maintain immunological tolerance. In 2014, Poe et al. reported that EndoU is a critical player in this pathway (pmc.ncbi.nlm.nih.gov). Their genetic studies in mice showed that EndoU is upregulated in B cells undergoing AICD (for example, in anergic B cells chronically exposed to self-antigen) (pmc.ncbi.nlm.nih.gov). When EndoU was knocked out or disrupted, these B cells failed to undergo cell death – EndoU loss prevented AICD, allowing potentially autoreactive B cells to survive (pmc.ncbi.nlm.nih.gov). Mechanistically, EndoU deficiency was associated with abnormally high levels of the c-Myc oncoprotein in those B cells (pmc.ncbi.nlm.nih.gov). Normally, EndoU activity appears to help downregulate c-Myc (a key driver of cell proliferation) post-transcriptionally, presumably by degrading c-Myc mRNA or a regulatory RNA that affects c-Myc (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In cells with functional EndoU, c-Myc levels drop and the cells are more prone to apoptosis after activation; but in EndoU-knockout B cells, c-Myc remains elevated, promoting continued survival and proliferation (pmc.ncbi.nlm.nih.gov). These findings revealed that EndoU defines a novel post-transcriptional checkpoint in B cell tolerance (pmc.ncbi.nlm.nih.gov). By cleaving specific RNA targets (like c-Myc transcripts or related noncoding RNAs), EndoU tips the balance toward apoptosis in over-stimulated or self-reactive B cells, thus preventing autoimmunity. This role aligns with EndoU’s broader function as an RNase that can selectively degrade RNAs to influence cell fate decisions. It is worth noting that EndoU’s expression in the immune system is tightly regulated – for instance, it is relatively low in naive B cells and most T cells, but induced in contexts like germinal center B cells or thymocyte development (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This cell-type specificity ensures that EndoU’s potent RNA-cleaving activity is deployed only in particular physiological situations (such as clonal deletion of autoreactive lymphocytes).

Neuronal and Developmental Roles: Beyond the immune and stress-response systems, ENDOU homologs have been implicated in several other biological processes. In Drosophila, the single EndoU-family gene (CG3303) is essential for neural function – loss of this gene caused locomotor defects and neurodegeneration linked to TDP-43 protein pathology (pmc.ncbi.nlm.nih.gov). This suggests EndoU may help clear neuronal RNA aggregates or regulate transcripts vital for neuron survival (possibly interacting with RNA-binding proteins like TDP-43). In C. elegans, the EndoU ortholog (endu-2) was found to regulate multiple traits including stress resistance and lifespan; for example, endu-2 mutants showed altered cold tolerance and developmental timing (pmc.ncbi.nlm.nih.gov). Endu-2 acted cell-autonomously in some tissues and non-autonomously in others, indicating it might process RNAs that can move between cells (or produce RNA fragments that have signaling roles) (pmc.ncbi.nlm.nih.gov). While these specific findings are in invertebrate models, they highlight the versatility of the EndoU family’s roles – from apoptosis and ER morphology to neural health and stress adaptation (pmc.ncbi.nlm.nih.gov). In all cases, a unifying theme is that EndoU enzymes modulate RNA populations to effect cellular changes. The precise RNA targets likely differ by organism and cell type (e.g. a snoRNA in oocytes, a uORF in CHOP mRNA, or c-Myc mRNA in B cells), but the core biochemical activity – cutting RNA at U-rich sites – is conserved. Notably, EndoU enzymes function as “switchable” RNases, kept latent until certain signals (like Ca²⁺ elevation, developmental cues, or stress conditions) trigger their activation (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This controllable nature distinguishes EndoU from constitutively active RNases and underscores its role in specific regulatory pathways rather than general RNA turnover.

Pathophysiological and Clinical Significance

Cancer Biomarker: ENDOU/PP11 has attracted interest as a biomarker in oncology for several decades. Because it was highly expressed in placenta, researchers in the 1980s explored whether placental proteins appear ectopically in cancers – indeed, ENDOU was detected in certain tumors and in patient sera. Early studies reported immunohistochemical presence of PP11 in ovarian adenocarcinomas (pmc.ncbi.nlm.nih.gov) and other “non-trophoblastic” tumors (tumors outside the placenta) (pmc.ncbi.nlm.nih.gov). These findings suggested that ENDOU might be a useful tumor marker, akin to other oncofetal proteins. More recently, large-scale genomic analyses have confirmed that ENDOU is abnormally upregulated in various cancers (pmc.ncbi.nlm.nih.gov). For example, an integrated transcriptomic study (Front. Oncol. 2021) identified ENDOU among the top genes associated with head and neck squamous cell carcinoma (HNSCC) progression (pmc.ncbi.nlm.nih.gov). ENDOU mRNA levels were higher in HNSCC tumors than in normal tissue, and correlated with advanced tumor stage (pmc.ncbi.nlm.nih.gov). Similarly, a 2021 meta-analysis of cervical cancer gene expression pinpointed ENDOU (along with the DNA repair enzyme FEN1) as a potential diagnostic marker for cervical squamous cell carcinoma, due to its consistent overexpression in tumor samples compared to controls (pmc.ncbi.nlm.nih.gov). Elevated ENDOU expression has also been noted in cancers of the breast and skin, and broadly in many carcinoma types (pmc.ncbi.nlm.nih.gov). These associations suggest that ENDOU may serve as a general marker of malignancy or tumor aggressiveness. In practical terms, ENDOU could be measured in tumor biopsies or blood (if the protein is secreted) to aid in cancer diagnosis or monitoring – though as of 2023 it is not yet a routine clinical test.

Potential Functional Role in Tumors: Beyond correlation, there is emerging evidence that ENDOU might actively influence tumor biology. Interestingly, ENDOU’s known functions (promoting apoptosis in immune cells, facilitating stress-induced cell death via CHOP, etc.) imply it could have context-dependent tumor suppressor effects. Consistent with this, one recent study in oral squamous cell carcinoma (OSCC) found that upregulating ENDOU can inhibit cancer cell proliferation (pmc.ncbi.nlm.nih.gov). In this 2023 study, a circular RNA (circ_0049396) was shown to sponge a microRNA (miR-663b) that normally represses ENDOU; the result was increased ENDOU expression, which in turn suppressed OSCC growth and invasion (pmc.ncbi.nlm.nih.gov). This suggests that ENDOU may trigger pro-death or anti-proliferative pathways in cancer cells, analogous to its role in promoting AICD of B cells. On the other hand, the possibility remains that some tumors hijack ENDOU’s activity for their benefit – for example, anecdotally, ENDOU might help tumor cells evade immune detection by degrading immunostimulatory RNAs in the tumor microenvironment. (Notably, many viruses use their own EndoU RNases to evade host immunity, as discussed below.) The net impact of ENDOU in cancer likely depends on context: it could contribute to tumor cell stress responses and apoptosis (good for the host), but if a tumor highly overexpresses ENDOU without undergoing death, it might be modulating the tumor milieu in subtler ways. Ongoing research is needed to clarify whether ENDOU is merely a bystander biomarker or an active player in oncogenesis. Regardless, ENDOU’s consistent presence in multiple cancer types makes it a promising biomarker for cancer diagnosis or prognosis, and potentially a target for therapeutic modulation if its role in tumor cell survival becomes clearer.

Immune and Viral Context: ENDOU’s involvement in immune cell homeostasis (e.g. B cell tolerance) indicates it could be relevant in autoimmunity or immunodeficiency. A deficiency or dysregulation of ENDOU might contribute to autoimmune disease by allowing self-reactive B or T cells to escape deletion. While no inherited ENDOU mutations have been definitively linked to human disease yet, mouse models lacking EndoU show a breakdown of B cell tolerance (pmc.ncbi.nlm.nih.gov), hinting that variations in ENDOU activity could influence autoantibody production or lymphoproliferative disorders. From another angle, ENDOU could be part of the host response to infections or tissue stress. Its induction during ER stress (to promote CHOP) is one example of a host protective mechanism. It is conceivable that ENDOU might be upregulated during certain viral infections as well, to help degrade viral RNA or amplify immune signaling – though concrete evidence for this in human cells is still lacking. Intriguingly, many viruses encode their own EndoU homologs as virulence factors. For instance, coronaviruses (such as SARS-CoV-2) have an EndoU domain in the nonstructural protein 15 (Nsp15); this viral RNase preferentially cleaves poly-uridine sequences in viral RNA to prevent detection by the host’s MDA5 sensor (pubmed.ncbi.nlm.nih.gov). The fact that viruses evolved EndoU enzymes underscores the biological importance of uridylate-specific RNases in the virus–host arms race. The human ENDOU might similarly target U-rich viral RNAs if they enter the secretory pathway or extracellular space, potentially contributing to antiviral defense, although this remains to be demonstrated.

Expert Commentary and Ongoing Research

As a relatively under-investigated protein, human ENDOU has become a subject of active research in recent years (2020–2024). Experts note that EndoU-like RNases represent a “poorly understood group” of enzymes, given their wide phylogenetic distribution and unique regulation (pmc.ncbi.nlm.nih.gov). The discovery of ENDOU’s calcium-dependent activation was a significant advance, answering a longstanding question of how eukaryotic EndoUs are controlled (pmc.ncbi.nlm.nih.gov). Structural biologists are continuing to probe ENDOU’s conformational dynamics – for example, Malard et al. (2024) used X-ray crystallography and NMR to detail the allosteric mechanism by which Ca²⁺ ions switch ENDOU from an inactive to an active state (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Such insights not only deepen our understanding of ENDOU’s enzymology, but also illustrate a broader principle of RNase regulation by metals. From a cell biology perspective, there is growing interest in ENDOU’s role in RNA regulation in specific compartments. Blower and colleagues’ work on XendoU established a paradigm of an RNase shaping the ER network (pmc.ncbi.nlm.nih.gov), raising the possibility that manipulating ENDOU could impact secretory organelles and protein secretion. In neuroscience, the link between an EndoU enzyme and TDP-43 pathology (Laneve et al., 2017) has opened questions about whether modulating EndoU activity could affect neurodegenerative disease processes that involve pathological RNA-protein aggregates (pmc.ncbi.nlm.nih.gov). Immunologists, on the other hand, see ENDOU as a new regulatory node in B cell biology – a 2014 JEM commentary highlighted EndoU as “a critical regulator of an RNA-dependent pathway controlling B cell survival”, underscoring its novelty in the immune context (pmc.ncbi.nlm.nih.gov).

Looking ahead, several lines of investigation are underway or envisioned: (1) Identifying endogenous RNA targets of ENDOU in various cell types (beyond CHOP and c-Myc mRNAs) using techniques like CLIP-seq and transcriptome analyses of ENDOU-knockout cells. This will clarify what RNA substrates ENDOU acts on in vivo and how it selects U-rich sites. (2) Physiological triggers and regulation – determining when and where ENDOU is activated. Calcium influx is one trigger, but there may be others (for example, interaction with specific protein partners or post-translational modifications) that modulate ENDOU’s activity or localization. (3) Therapeutic potential – evaluating ENDOU as a drug target or therapeutic tool. Since ENDOU can drive apoptosis in certain contexts, one could imagine activating ENDOU in cancer cells to induce cell death, or conversely inhibiting ENDOU in autoimmune conditions to prevent unwarranted cell deletion. Specific small-molecule inhibitors of ENDOU (or its Ca²⁺-binding site) could be developed, aided by the new structural data. There is also interest in ENDOU as a diagnostic marker: for example, measuring ENDOU levels in patient blood or tumor biopsies as part of a cancer diagnostic panel. Already, high ENDOU expression has been proposed as a prognostic indicator in cancers like HNSCC and cervical carcinoma (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov), and further validation may establish its utility in the clinic.

In summary, human ENDOU is a uridylate-specific endoribonuclease with a unique regulatory profile and a variety of biological roles. It operates at the crossroads of RNA metabolism and cellular signaling – cleaving RNAs in a highly controlled fashion to influence processes such as ER dynamics, stress responses, immune cell homeostasis, and possibly tumorigenesis. Recent research (2021–2024) has greatly advanced our understanding of ENDOU, from revealing its calcium-activated mechanism (pmc.ncbi.nlm.nih.gov) to discovering its targeted impact on mRNA translation (pubmed.ncbi.nlm.nih.gov). Yet, many aspects of ENDOU function remain to be explored, making it an exciting topic in molecular biology and a potential link between RNA biology, cell physiology, and disease. The continued study of ENDOU and its homologs is likely to yield further insights into how cells utilize specialized RNases to regulate gene expression and maintain homeostasis in complex environments.

References: (Key references are cited in text above with inline citations. Publication details include: Bohn & Winckler 1980 (placental protein 11 discovery); Laneve et al. 2008 J. Biol. Chem. (demonstration of PP11’s RNase activity); Schwarz & Blower 2014 J. Cell Biol. (XendoU in ER network); Poe et al. 2014 J. Exp. Med. (EndoU in B cell AICD); Loffreda et al. 2021 Nucleic Acids Res. (ENDOU cleavage of CHOP uORF); Xu et al. 2021 Front. Oncol. (ENDOU in HNSCC); Malard et al. 2024 Nat. Commun. (Ca²⁺-activated EndoU structure), among others.) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov)

Citations

1. AnnotationURLCitation(end_index=351, start_index=230, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=other%20species,It%20is%20also%20now')
2. AnnotationURLCitation(end_index=607, start_index=486, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=other%20species,It%20is%20also%20now')
3. AnnotationURLCitation(end_index=915, start_index=747, title='ENDOU endonuclease, poly(U) specific [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/8909#:~:text=based%20on%20its%20high%20expression,alternatively%20spliced%20transcript%20variants%20encoding')
4. AnnotationURLCitation(end_index=1343, start_index=1192, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=other%20species,various%20cancers%2C%20including%20squamous%20cell')
5. AnnotationURLCitation(end_index=1757, start_index=1589, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=releases%20small%20nucleolar%20RNAs%20from,shown%20that%20hEndoU%20cleaves%20single')
6. AnnotationURLCitation(end_index=2081, start_index=1942, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=The%20endoribonuclease%20EndoU,6%7D.%20XendoU%2C%20the')
7. AnnotationURLCitation(end_index=2486, start_index=2329, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=sometimes%20somatomedin%20B%20,that%20cellular%20calcium%20levels%20rise')
8. AnnotationURLCitation(end_index=2823, start_index=2666, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=sometimes%20somatomedin%20B%20,that%20cellular%20calcium%20levels%20rise')
9. AnnotationURLCitation(end_index=3314, start_index=3142, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=the%20endoribonuclease%20XendoU%20in%20the,domain%20compared%20to%20eukaryotic%20EndoUs')
10. AnnotationURLCitation(end_index=3936, start_index=3764, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=the%20endoribonuclease%20XendoU%20in%20the,domain%20compared%20to%20eukaryotic%20EndoUs')
11. AnnotationURLCitation(end_index=4222, start_index=4069, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=differences%20in%20their%20activation%20requirements,Lys%20catalytic')
12. AnnotationURLCitation(end_index=4538, start_index=4385, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=differences%20in%20their%20activation%20requirements,Lys%20catalytic')
13. AnnotationURLCitation(end_index=4989, start_index=4817, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=catalytic%20domain%20requires%20divalent%20metal,the%20catalytic%20core%20to%20modulate')
14. AnnotationURLCitation(end_index=5393, start_index=5221, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=catalytic%20domain%20requires%20divalent%20metal,the%20catalytic%20core%20to%20modulate')
15. AnnotationURLCitation(end_index=5809, start_index=5628, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=and%20computational%20techniques%20along%20with,findings%20suggest%20that%20similar%20mechanisms')
16. AnnotationURLCitation(end_index=6270, start_index=6149, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=other%20species,It%20is%20also%20now')
17. AnnotationURLCitation(end_index=6602, start_index=6440, title='ENDOU endonuclease, poly(U) specific [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/8909#:~:text=Expression%20Biased%20expression%20in%20esophagus,other%20tissue%20See%20more%20Orthologs')
18. AnnotationURLCitation(end_index=7055, start_index=6894, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=In%20mammals%2C%20EndoU%20expression%20is,3%20transition%20and%20progressing')
19. AnnotationURLCitation(end_index=7796, start_index=7639, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=sometimes%20somatomedin%20B%20,that%20cellular%20calcium%20levels%20rise')
20. AnnotationURLCitation(end_index=8070, start_index=7913, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=sometimes%20somatomedin%20B%20,that%20cellular%20calcium%20levels%20rise')
21. AnnotationURLCitation(end_index=8305, start_index=8193, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=cancers,25%20%E2%80%93%2033')
22. AnnotationURLCitation(end_index=8920, start_index=8738, title='ENDOU endonuclease, poly(U) specific [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/8909#:~:text=1.%20NM_001172439.2%20%E2%86%92%20NP_001165910.1%20%C2%A0uridylate,endoribonuclease%20isoform%201%20precursor')
23. AnnotationURLCitation(end_index=9481, start_index=9369, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=cancers,25%20%E2%80%93%2033')
24. AnnotationURLCitation(end_index=10097, start_index=9921, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=horizontal%20acquisition%20of%20a%20prokaryotic,Mus%20musculus%2C%20Homo%20sapiens%2C%20and')
25. AnnotationURLCitation(end_index=10486, start_index=10374, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=cancers,25%20%E2%80%93%2033')
26. AnnotationURLCitation(end_index=11127, start_index=10994, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=,CG3303%20is%20an%20essential%20endoribonuclease')
27. AnnotationURLCitation(end_index=11412, start_index=11317, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=cancers,28')
28. AnnotationURLCitation(end_index=11720, start_index=11597, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=characterized%20that%20EndoU,dependent')
29. AnnotationURLCitation(end_index=12580, start_index=12423, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=sometimes%20somatomedin%20B%20,that%20cellular%20calcium%20levels%20rise')
30. AnnotationURLCitation(end_index=13393, start_index=13256, title='Poly(U)-specific endoribonuclease ENDOU promotes translation of human CHOP mRNA by releasing uORF element-mediated inhibition - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33511665/#:~:text=or%20ENDOU,facilitating%20translation%20of%20the%20cleaved')
31. AnnotationURLCitation(end_index=13670, start_index=13530, title='Poly(U)-specific endoribonuclease ENDOU promotes translation of human CHOP mRNA by releasing uORF element-mediated inhibition - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33511665/#:~:text=inhibitory%20uORF%20in%20the%20transcript,Furthermore%2C%20we')
32. AnnotationURLCitation(end_index=13973, start_index=13814, title='Poly(U)-specific endoribonuclease ENDOU promotes translation of human CHOP mRNA by releasing uORF element-mediated inhibition - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33511665/#:~:text=transcript%20at%20position%2080G,translation%20resulting%20in%20increased%20CHOP')
33. AnnotationURLCitation(end_index=14239, start_index=14085, title='Poly(U)-specific endoribonuclease ENDOU promotes translation of human CHOP mRNA by releasing uORF element-mediated inhibition - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33511665/#:~:text=translation%20of%20specific%20factors%20such,eIF2%CE%B1%20are%20nonetheless')
34. AnnotationURLCitation(end_index=14612, start_index=14475, title='Poly(U)-specific endoribonuclease ENDOU promotes translation of human CHOP mRNA by releasing uORF element-mediated inhibition - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33511665/#:~:text=or%20ENDOU,facilitating%20translation%20of%20the%20cleaved')
35. AnnotationURLCitation(end_index=14999, start_index=14837, title='Poly(U)-specific endoribonuclease ENDOU promotes translation of human CHOP mRNA by releasing uORF element-mediated inhibition - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33511665/#:~:text=required%20for%20maximal%20translation%20of,its%20inhibition%20and%20allowing%20the')
36. AnnotationURLCitation(end_index=15924, start_index=15801, title='EndoU is a novel regulator of AICD during peripheral B cell selection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3892980/#:~:text=auto,a%20critical%20regulator%20of%20an')
37. AnnotationURLCitation(end_index=16238, start_index=16090, title='EndoU is a novel regulator of AICD during peripheral B cell selection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3892980/#:~:text=evolutionarily%20conserved%20single,sHEL%29%20as%20the%20cognate')
38. AnnotationURLCitation(end_index=16533, start_index=16410, title='EndoU is a novel regulator of AICD during peripheral B cell selection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3892980/#:~:text=auto,a%20critical%20regulator%20of%20an')
39. AnnotationURLCitation(end_index=16777, start_index=16654, title='EndoU is a novel regulator of AICD during peripheral B cell selection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3892980/#:~:text=auto,a%20critical%20regulator%20of%20an')
40. AnnotationURLCitation(end_index=17101, start_index=16978, title='EndoU is a novel regulator of AICD during peripheral B cell selection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3892980/#:~:text=auto,a%20critical%20regulator%20of%20an')
41. AnnotationURLCitation(end_index=17230, start_index=17102, title='EndoU is a novel regulator of AICD during peripheral B cell selection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3892980/#:~:text=match%20at%20L90%20Shlomchik%2C%202008%29,Ag')
42. AnnotationURLCitation(end_index=17567, start_index=17444, title='EndoU is a novel regulator of AICD during peripheral B cell selection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3892980/#:~:text=auto,a%20critical%20regulator%20of%20an')
43. AnnotationURLCitation(end_index=17804, start_index=17676, title='EndoU is a novel regulator of AICD during peripheral B cell selection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3892980/#:~:text=match%20at%20L90%20Shlomchik%2C%202008%29,Ag')
44. AnnotationURLCitation(end_index=18529, start_index=18368, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=In%20mammals%2C%20EndoU%20expression%20is,3%20transition%20and%20progressing')
45. AnnotationURLCitation(end_index=18630, start_index=18530, title='EndoU is a novel regulator of AICD during peripheral B cell selection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3892980/#:~:text=with%204.4,EndoU')
46. AnnotationURLCitation(end_index=19315, start_index=19173, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=free%20article%20%5D%20,2%20regulates%20multiple%20traits')
47. AnnotationURLCitation(end_index=19810, start_index=19704, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=,%26%20Aravind%2C%20L')
48. AnnotationURLCitation(end_index=20111, start_index=20005, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=,%26%20Aravind%2C%20L')
49. AnnotationURLCitation(end_index=20399, start_index=20304, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=cancers,28')
50. AnnotationURLCitation(end_index=21090, start_index=20909, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=and%20computational%20techniques%20along%20with,findings%20suggest%20that%20similar%20mechanisms')
51. AnnotationURLCitation(end_index=21244, start_index=21091, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=differences%20in%20their%20activation%20requirements,Lys%20catalytic')
52. AnnotationURLCitation(end_index=21986, start_index=21872, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=%5BGoogle%20Scholar%5D%20,DOI')
53. AnnotationURLCitation(end_index=22196, start_index=22054, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=%5BPubMed%5D%20%5BGoogle%20Scholar%5D%20,Google%20Scholar')
54. AnnotationURLCitation(end_index=22579, start_index=22419, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=recognized%20as%20a%20biomarker%20in,Across%20other%20eukaryotes%2C%20EndoU')
55. AnnotationURLCitation(end_index=22867, start_index=22765, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=,Google%20Scholar')
56. AnnotationURLCitation(end_index=23081, start_index=22979, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=,Google%20Scholar')
57. AnnotationURLCitation(end_index=23449, start_index=23357, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=,PubMed')
58. AnnotationURLCitation(end_index=23736, start_index=23576, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=recognized%20as%20a%20biomarker%20in,Across%20other%20eukaryotes%2C%20EndoU')
59. AnnotationURLCitation(end_index=24638, start_index=24536, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=,Google%20Scholar')
60. AnnotationURLCitation(end_index=24958, start_index=24856, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=,Google%20Scholar')
61. AnnotationURLCitation(end_index=26669, start_index=26541, title='EndoU is a novel regulator of AICD during peripheral B cell selection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3892980/#:~:text=match%20at%20L90%20Shlomchik%2C%202008%29,Ag')
62. AnnotationURLCitation(end_index=27687, start_index=27509, title='Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/32198201/#:~:text=Coronavirus%20endoribonuclease%20targets%20viral%20polyuridine,the%20target%20of%20EndoU%20activity')
63. AnnotationURLCitation(end_index=28502, start_index=28363, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=The%20endoribonuclease%20EndoU,6%7D.%20XendoU%2C%20the')
64. AnnotationURLCitation(end_index=28835, start_index=28659, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=vertebrate%20RNase%20A%2C%20specifically%20featuring,activity%20of%20the%20catalytic%20core')
65. AnnotationURLCitation(end_index=29276, start_index=29095, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=and%20computational%20techniques%20along%20with,findings%20suggest%20that%20similar%20mechanisms')
66. AnnotationURLCitation(end_index=29461, start_index=29277, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=Eucaryotic%20EndoU%20are%20endoribonucleases%20that,ions%20allosterically%20activate%20the%20enzyme')
67. AnnotationURLCitation(end_index=29919, start_index=29824, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=cancers,28')
68. AnnotationURLCitation(end_index=30422, start_index=30280, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=free%20article%20%5D%20,2%20regulates%20multiple%20traits')
69. AnnotationURLCitation(end_index=30810, start_index=30687, title='EndoU is a novel regulator of AICD during peripheral B cell selection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3892980/#:~:text=auto,a%20critical%20regulator%20of%20an')
70. AnnotationURLCitation(end_index=32283, start_index=32181, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=,Google%20Scholar')
71. AnnotationURLCitation(end_index=32376, start_index=32284, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=,PubMed')
72. AnnotationURLCitation(end_index=33110, start_index=32938, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=catalytic%20domain%20requires%20divalent%20metal,the%20catalytic%20core%20to%20modulate')
73. AnnotationURLCitation(end_index=33324, start_index=33166, title='Poly(U)-specific endoribonuclease ENDOU promotes translation of human CHOP mRNA by releasing uORF element-mediated inhibition - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33511665/#:~:text=internal%20ribosome%20entry%20site%20,translation%20of%20the%20downstream%20ORF')
74. AnnotationURLCitation(end_index=34401, start_index=34276, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=placenta,has%20been%20proposed%20to%20be')
75. AnnotationURLCitation(end_index=34525, start_index=34402, title='EndoU is a novel regulator of AICD during peripheral B cell selection - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3892980/#:~:text=auto,a%20critical%20regulator%20of%20an')
76. AnnotationURLCitation(end_index=34663, start_index=34526, title='Poly(U)-specific endoribonuclease ENDOU promotes translation of human CHOP mRNA by releasing uORF element-mediated inhibition - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/33511665/#:~:text=or%20ENDOU,facilitating%20translation%20of%20the%20cleaved')
77. AnnotationURLCitation(end_index=34817, start_index=34664, title='Molecular basis for the calcium-dependent activation of the ribonuclease EndoU - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11961692/#:~:text=differences%20in%20their%20activation%20requirements,Lys%20catalytic')

Deep Research Report: ENDOU (human)

Generated using OpenAI Deep Research API

ENDOU (Poly(U)-specific Endoribonuclease) Gene in Homo sapiens

Gene Function and Molecular Mechanisms

The human ENDOU gene encodes a poly(U)-specific endoribonuclease that binds and cleaves single-stranded RNA, particularly at uridylate-rich sequences (pmc.ncbi.nlm.nih.gov). Unlike classical RNase A, which is secreted and cuts RNA without metal cofactors, ENDOU’s activity is Mn²⁺-dependent and cuts at the 5′-side of uridine residues, generating 2′,3′-cyclic phosphate termini on the cleaved RNA fragments (pmc.ncbi.nlm.nih.gov). Biochemical studies demonstrated that recombinant ENDOU (also known as placental protein 11, PP11) can bind polyuridine stretches and selectively cleave RNA at UU or GU motifs, reflecting a preference for U-rich targets (pmc.ncbi.nlm.nih.gov). This endoribonuclease activity was a surprising discovery because ENDOU was initially misannotated as a serine protease based on sequence similarity; subsequent structural and mutagenesis analyses revealed that it actually shares striking parallels with amphibian XendoU ribonuclease, not proteases (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The catalytic mechanism of ENDOU involves a His–His–Lys triad in the active site, analogous to that of RNase A: two histidines act as general acid/base catalysts, and a lysine stabilizes the transition state (www.ncbi.nlm.nih.gov). Point mutations in these conserved active-site residues abolish the nuclease activity (pmc.ncbi.nlm.nih.gov) (www.ncbi.nlm.nih.gov), confirming that ENDOU uses a conserved ribonucleolytic mechanism. Through this enzymatic activity, ENDOU likely participates in RNA processing or turnover; for example, its Xenopus homolog (XendoU) is involved in small nucleolar RNA processing, and the viral homolog Nsp15 is essential for coronavirus RNA replication (pmc.ncbi.nlm.nih.gov). By analogy, human ENDOU may process or degrade specific cellular RNAs, although its precise endogenous RNA substrates remain to be fully identified.

Cellular Localization and Subcellular Components

ENDOU is a secreted protein, synthesized as a precursor with an N-terminal signal peptide that directs it into the secretory pathway (v20.proteinatlas.org) (v20.proteinatlas.org). It is predicted to be extracellular (locally secreted) rather than retained on the plasma membrane (v20.proteinatlas.org). Consistent with this, immunohistochemistry shows ENDOU in the extracellular space (GO:0005615) and in the cytoplasm (GO:0005737) of producing cells (v20.proteinatlas.org) (v20.proteinatlas.org). In placenta and certain epithelia, ENDOU protein exhibits a punctate cytoplasmic distribution, likely reflecting localization to secretory granules or vesicles prior to secretion (v20.proteinatlas.org). There is no strong evidence that ENDOU localizes to the nucleus or other organelles in human cells. Instead, once secreted, it presumably functions in the extracellular region (GO:0005576), possibly in the immediate vicinity of the cells that produce it (v20.proteinatlas.org) (v20.proteinatlas.org). Notably, ENDOU is not detectable in blood plasma under normal conditions (v20.proteinatlas.org), suggesting it acts locally (e.g. in tissues like placenta or mucosa) rather than as a circulating enzyme. In summary, ENDOU is a secreted, extracellular ribonuclease that also resides transiently in the cytosol of secretory cells, aligning with its designation as a locally acting secreted enzyme.

Biological Processes Involvement

Given its ribonuclease activity, ENDOU is implicated in RNA metabolic processes. By cleaving single-stranded RNAs, it likely contributes to RNA catabolic process (degradation of RNA) or the processing of specific noncoding RNAs. In Xenopus, the homolog XendoU participates in snoRNA biogenesis, and by homology ENDOU may also assist in processing small RNAs required for ribosome biogenesis (pmc.ncbi.nlm.nih.gov), though a direct role in human snoRNA processing has not been confirmed. Instead, emerging evidence links ENDOU to the immune system: in mice, Endou was identified as a critical regulator of activation-induced cell death (AICD) in B cells, a process that eliminates self-reactive B lymphocytes as part of peripheral tolerance (pmc.ncbi.nlm.nih.gov). Mouse B cells lacking Endou are resistant to AICD and fail to downregulate c-Myc upon antigen receptor engagement, indicating that Endou normally promotes apoptosis in overstimulated or auto-reactive B cells (pmc.ncbi.nlm.nih.gov). This places ENDOU in a novel RNA-mediated pathway of immune tolerance, where its ribonuclease activity might degrade specific mRNAs or non-coding RNAs to trigger cell death in activated B cells (pmc.ncbi.nlm.nih.gov). Additionally, ENDOU has been associated with trophoblast invasion and tumor progression. Both placental syncytiotrophoblasts and malignant tumors (especially of placenta origin) are invasive tissues, and the high ENDOU expression in these cells suggests it could facilitate cell invasion or immune evasion in the microenvironment (pmc.ncbi.nlm.nih.gov). For instance, ENDOU might degrade extracellular RNAs that would otherwise activate immune responses or influence intercellular communication, thereby creating a milieu favorable for tissue invasion. While the exact biological processes are still being elucidated, current data indicate that ENDOU plays roles in RNA turnover, apoptotic processes in immune regulation, and possibly in supporting the unique invasive functions of placental and cancer cells.

Disease Associations and Phenotypes

ENDOU was originally described as a tumor-associated placental protein and is now studied as a potential tumor marker. It is notably expressed in certain cancers: one survey found ENDOU (PP11) upregulated in 66.7% of mucinous ovarian cystadenocarcinomas and 57.1% of serous ovarian carcinomas, while absent in normal ovarian tissue (pmc.ncbi.nlm.nih.gov). ENDOU was also detected in ~47% of breast carcinomas and ~38% of testicular and gastric cancers examined (pmc.ncbi.nlm.nih.gov). Because of this oncofetal expression pattern (present in tumors and placenta but low in most normal adult tissues), ENDOU has been proposed as a diagnostic marker for cancers like ovarian carcinoma (pmc.ncbi.nlm.nih.gov). Its functional role in cancer is not fully understood, but the correlation with invasive tumors suggests ENDOU might contribute to tumor progression or metastasis – possibly by remodeling the tumor microenvironment or helping tumor cells evade RNA-mediated immune surveillance (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). In support of a functional role, in vitro studies have noted that high ENDOU levels in head and neck cancer correlate with better prognosis (a favorable prognostic marker) (v20.proteinatlas.org), hinting that ENDOU could influence tumor behavior or patient response. Aside from cancer, ENDOU’s role in autoimmunity is of interest due to its function in B cell tolerance; dysregulation of ENDOU could, in theory, affect autoimmune disease development, though no specific autoimmune disorder has been directly linked to ENDOU in humans yet. There are also references associating ENDOU with a congenital disorder (distal arthrogryposis type 6) via bioinformatic text-mining (www.genecards.org), but no direct genetic evidence currently connects ENDOU mutations to this phenotype. Overall, ENDOU’s main disease relevance lies in oncology (as a marker and potential modulator of tumorigenesis) and possibly immunology (tolerance and autoimmunity), warranting further clinical research.

Protein Domains and Structural Features

The ENDOU protein is 410 amino acids in length (∼46.9 kDa) (www.genecards.org), comprising a signal peptide (for secretion) and a large enzymatic domain. It belongs to the XendoU/EndoU endoribonuclease family, whose members share a conserved catalytic core. The enzyme’s active site contains a His–His–Lys motif required for catalysis (www.ncbi.nlm.nih.gov). This motif lies in the central region of the protein and is responsible for binding and cleaving the RNA substrate via general acid-base catalysis (by the two histidines) and transition state stabilization (by the lysine) (www.ncbi.nlm.nih.gov). ENDOU’s tertiary structure is expected to be similar to other family members (e.g., viral Nsp15 endonuclease), which have a mixed α/β fold forming a nuclease domain (www.ncbi.nlm.nih.gov). Although the high-resolution crystal structure of human ENDOU has not been published as of yet, homology models and mutagenesis data support a structure with similarity to X. laevis XendoU (pmc.ncbi.nlm.nih.gov). ENDOU is likely a monomeric enzyme in its secreted form, though some homologs (like coronavirus Nsp15) assemble into oligomers for full activity. The protein is predicted to have several disulfide bonds, consistent with being a secreted glycoprotein; multiple cysteine residues are present (including in Cys-rich segments) that probably form intra-molecular disulfide linkages important for structural stability in the extracellular environment. ENDOU also contains consensus N-linked glycosylation sites, suggesting it is glycosylated in the endoplasmic reticulum and Golgi. Indeed, placental PP11 was characterized as a glycoprotein in early studies (pmc.ncbi.nlm.nih.gov). There are no known additional large domains in ENDOU – the protein is essentially a single-domain ribonuclease (after the signal sequence is cleaved) with poly(U)-specific RNase activity. Notably, earlier names like PRSS26 (serine protease 26) arose from a presumed trypsin-like domain; however, we now know ENDOU’s domain is an RNase fold, not a serine protease, despite superficial sequence motifs. In summary, ENDOU’s structure features a secretory signal peptide, a core endoribonuclease domain with a His–His–Lys catalytic triad, and likely several post-translational modifications (disulfides and N-glycans) that support its function as a secreted enzyme.

Expression Patterns and Regulation

Tissue distribution: ENDOU shows a highly skewed expression pattern. It was first identified in the placenta, and indeed placenta (specifically the syncytiotrophoblast layer) exhibits very high ENDOU expression (pmc.ncbi.nlm.nih.gov) (v20.proteinatlas.org). In early reports, ENDOU/PP11 was undetectable in most adult tissues aside from placenta (pmc.ncbi.nlm.nih.gov). Modern transcriptome analyses confirm that ENDOU is tissue-enhanced in placenta, and also in a few other tissues such as the esophagus and tongue, which have squamous epithelial cells (v20.proteinatlas.org). Immunohistochemistry data indicate prominent cytoplasmic ENDOU expression in placental trophoblasts and in stratified squamous epithelia (e.g. epidermal keratinocytes, esophageal lining) (v20.proteinatlas.org) (v20.proteinatlas.org). By contrast, most other tissues (brain, muscle, etc.) show little to no ENDOU expression. Notably, immune cells do not express ENDOU at baseline (v20.proteinatlas.org), which correlates with its absence from blood and restriction to specific cell types. There is some expression in skin and gastrointestinal tract epithelia, but overall ENDOU is best characterized as an oncofetal or tissue-selective gene.

Regulation: The factors regulating ENDOU expression are not fully defined. Because ENDOU is elevated in placenta, it may be influenced by pregnancy-related hormones or transcription factors active in trophoblasts. Its induction in tumors suggests that oncogenic pathways or epigenetic changes can upregulate ENDOU in cancer cells – for example, hypomethylation or specific transcription factors in trophoblast-like cancers might activate ENDOU transcription (this is an area of ongoing research). In the immune context, while resting lymphocytes do not express ENDOU, it might be induced upon B cell activation or stress, as implied by the phenotype of Endou-deficient mice (where B cells likely expressed it during activation to undergo AICD) (pmc.ncbi.nlm.nih.gov). Thus, ENDOU expression could be conditional, turning on in B cells only under certain stimulation conditions to enforce tolerance. Additionally, multiple alternative splicing isoforms of ENDOU mRNA exist (www.ncbi.nlm.nih.gov), which might be differentially expressed or regulated. However, the dominant transcript encodes the secreted form described above. In summary, ENDOU is expressed strongly in placenta and some epithelia (possibly under hormonal or developmental regulation), is aberrantly expressed in a variety of cancers, and may be inducible in immune cells during specific activation events. The Gene Ontology (GO) classification reflects this pattern: ENDOU’s RNA is “detected in some tissues” and shows group-enriched expression in syncytiotrophoblasts and suprabasal keratinocytes (v20.proteinatlas.org), consistent with the known biology of this gene.

Evolutionary Conservation

ENDOU is an evolutionarily ancient gene, with homologs found across a broad range of organisms. Orthologs of ENDOU (or closely related endoribonucleases) exist in vertebrates (e.g., mammals, birds, amphibians) and even in invertebrates such as nematode worms, indicating that this gene family was present in a common ancestor of bilaterian animals (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). The family is defined by the EndoU/XendoU domain with the His–His–Lys catalytic triad, and these key residues are conserved from Xenopus (frog) to Homo sapiens (www.ncbi.nlm.nih.gov). The strong conservation of the active site suggests that the fundamental biochemical function – cleaving RNA at uridines – has been maintained throughout evolution. Intriguingly, EndoU-related enzymes are also found in viruses: many coronaviruses encode an endoribonuclease called Nsp15 (also known as NendoU) that is clearly homologous to ENDOU (pmc.ncbi.nlm.nih.gov). This viral enzyme is crucial for viral RNA processing and immune evasion, hinting that viruses may have co-opted an ancestral cellular EndoU-like enzyme for their lifecycle. There is even evidence of EndoU-like domains in certain bacterial toxin systems, implying that the basic fold and mechanism have been adapted in different biological contexts (www.ncbi.nlm.nih.gov). In mammals, ENDOU is syntenic and relatively conserved; for example, the mouse Endou shares high sequence identity with human ENDOU and mirrors its biochemical activity (the mouse protein can likewise cleave poly(U) RNAs and has the same catalytic motif). Functional conservation is illustrated by the mouse phenotype in B cells (pmc.ncbi.nlm.nih.gov), suggesting an ancient role in immune regulation or RNA metabolism that might be shared across species. Therefore, ENDOU represents a gene with deep evolutionary roots, conserved catalytic machinery, and diversified roles – from snoRNA processing in amphibian oocytes to antiviral defense in viruses to immunological and placental functions in mammals. The evolutionary retention of ENDOU underscores the importance of its RNA cleavage activity in fundamental cellular and physiological processes.

Key Experimental Evidence and Literature

• Identification as Placental Protein 11 (1980s): ENDOU was first isolated in the 1980s as placental protein 11 (PP11), one of several glycoproteins uniquely abundant in term placentas (pmc.ncbi.nlm.nih.gov). Initial characterization (cDNA cloning in 1990) predicted it to be a secreted trypsin-like protease, based on sequence motifs (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). It was noted that PP11 appeared placenta-specific and was undetectable in other normal tissues (pmc.ncbi.nlm.nih.gov).

• Tumor Marker Discovery: Subsequent studies in the 1990s and 2000s found that ENDOU/PP11 is expressed in many tumors, especially germ cell and epithelial cancers. For example, Huppertz et al. and others reported high PP11 levels in ovarian cancer and trophoblastic tumors (choriocarcinoma) (pmc.ncbi.nlm.nih.gov). By the 2000s, ENDOU was recognized as an oncofetal antigen that could serve as a molecular marker for tumor diagnosis (pmc.ncbi.nlm.nih.gov).

• Laneve et al. 2008 (J. Biol. Chem.): This pivotal study redefined ENDOU’s function. Laneve and colleagues showed that recombinant human PP11 is not a protease but an endoribonuclease (pmc.ncbi.nlm.nih.gov). They demonstrated Mn²⁺-dependent RNA cleavage at uridines, producing cyclic phosphate ends, and identified key active-site residues by homology modeling and mutagenesis (pmc.ncbi.nlm.nih.gov). This work firmly established ENDOU as a poly(U)-specific endoribonuclease, related to Xenopus XendoU and coronavirus Nsp15 (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

• Poe et al. 2014 (J. Exp. Med.): This study uncovered a biological role for EndoU in immune tolerance. Using a mouse model, the authors found that EndoU is a “major regulator of B cell survival” during activation-induced cell death (pmc.ncbi.nlm.nih.gov). Mice with Endou disruption had B cells that resisted AICD, implicating EndoU’s RNase activity in an RNA-dependent cell death pathway. This provided the first in vivo evidence of ENDOU’s function in regulating cell fate (apoptosis) and immunity (pmc.ncbi.nlm.nih.gov).

• Structural and Mechanistic Studies: Various structural biology efforts (e.g., Ivanov et al. 2004; Guarino et al. 2005) on XendoU and Nsp15 have informed our understanding of ENDOU. These studies revealed the His–His–Lys catalytic triad and a conserved fold for EndoU-family nucleases (www.ncbi.nlm.nih.gov). While a human ENDOU crystal structure is pending, modeling suggests a similar configuration. Such studies also highlight mechanistic parallels to RNase A, despite ENDOU’s requirement for metal ions (www.ncbi.nlm.nih.gov).

• Database Annotations and Current Knowledge: Comprehensive databases corroborate these findings. UniProt and Gene Ontology annotations list ENDOU as an RNA-binding endoribonuclease (with GO terms for RNA binding and endoribonuclease activity) and place it in the extracellular region (v20.proteinatlas.org) (v20.proteinatlas.org). The Human Protein Atlas confirms ENDOU protein expression in placenta and certain epithelia and its secretion localization (v20.proteinatlas.org) (v20.proteinatlas.org). Ongoing research is exploring ENDOU’s substrates and its potential as a drug target or diagnostic marker in cancer and immune-related conditions.

Relevant GO Terms

• Molecular Function: RNA binding (GO:0003723) (v20.proteinatlas.org); endoribonuclease activity (GO:0004521), cleaving RNA to yield 2′,3′-cyclic phosphates (pmc.ncbi.nlm.nih.gov); metal ion binding (e.g., manganese) (GO:0046872) (v20.proteinatlas.org). (Historically, ENDOU was misannotated with serine-type peptidase activity, but this has been corrected as it has no protease activity (pmc.ncbi.nlm.nih.gov).)

• Biological Process: RNA catabolic process/RNA metabolism (GO:0016075), particularly degradation of single-stranded RNA (pmc.ncbi.nlm.nih.gov). Implicated in activation-induced cell death of B cells (peripheral B cell tolerance) and apoptotic process (GO:0006915) (pmc.ncbi.nlm.nih.gov). Possibly involved in small nucleolar RNA processing (GO:0016074) by analogy to XendoU (pmc.ncbi.nlm.nih.gov), and in immune system process (GO:0002376) through its role in tolerance. Also associated with multicellular organism development (placental development) and cell invasion in the context of placentation and cancer (though no specific GO term is yet assigned for the latter).

• Cellular Component: Extracellular region (GO:0005576) and extracellular space (GO:0005615) (v20.proteinatlas.org) (v20.proteinatlas.org); cytoplasm (GO:0005737) (within secretory cells, prior to secretion) (v20.proteinatlas.org). ENDOU is secreted and not typically associated with organelle membranes or the nucleus. (Note: ENDOU lacks a transmembrane domain and is described as a locally secreted soluble protein (v20.proteinatlas.org).)

Each of these Gene Ontology terms is supported by experimental findings and annotations in genomic databases, reflecting our current understanding of ENDOU’s role as an extracellular endoribonuclease involved in RNA processing, immune regulation, and placental/tumor physiology. (v20.proteinatlas.org) (pmc.ncbi.nlm.nih.gov)